Title
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure Substudy of the RE-LY trial
Publication Date
2015
Journal Title
Thromb Haemost
Abstract
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain. We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders. Bridging was used more during warfarin interruption than dabigatran interruption (27.5% vs 15.4%; p
Volume Number
113
Issue Number
3
Pages
625-632
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
General Internal Medicine
PMID
DOI
10.1160/th14-04-0305
This document is currently not available here.
COinS
Comments
Hofstra Northwell School of Medicine and Northwell Health currently do not subscribe to this title. If you are an affiliate and would like to access the full text please request it via interlibrary loan via Hofstra Northwell School of Medicine ILL (faculty and students only) or Northwell Health ILL